Why IQVIA Holdings Inc.’s (IQV) Stock Is Up 14.90%
As of Tuesday, July 28, IQVIA Holdings Inc.’s IQV share price has surged by 14.90%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Commentary & Analysis
What You Need to Know About IQVIA Holdings Inc.'s Q3 Earnings
IQVIA Holdings Inc.'s fiscal Q3 earnings report was released on Tuesday, July 28. Let's dive in to see if (IQV) missed or beat analyst's expectations.Michael Rose
Why IQVIA Holdings Inc.’s (IQV) Stock Is Up 13.03%
As of Tuesday, July 28, IQVIA Holdings Inc.’s IQV share price has surged by 13.03%, which has investors questioning if this is right time to sell.Tudor Pop
Why IQVIA Holdings Inc.’s (IQV) Stock Is Up 5.48%
As of Thursday, July 23, IQVIA Holdings Inc.’s IQV share price has surged by 5.48%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is IQVIA Holdings Inc. (IQV) Overvalued?
We dive into why IQVIA Holdings Inc. (IQV) could be considered overvalued on 2026-07-17, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | IQV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $39,140.2 | $1,774.7 | 92% |
|
| Shares Out (Mil) | 167.3 | 94.8 | 73% |
|
| Institutional Ownership | 99.0% | 90.1% | 84% |
|
| Float (Mil) | 156.2 | 69.9 | 70% |
|
| Beta | 1.20 | 1.20 | 70% |
|
| Avg Daily Volume (000s) | 1,777 | 838 | 80% |
|
| Price Change (52-week) |
22.2% | 81.0% | 64% |
|
| Growth | IQV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.5% | 7.8% | 48% |
|
| Net Income (5yr) | 37.3% | (13.7%) | 89% |
|
| EPS (5yr) | 40.5% | 0.7% | 88 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.5%) | (15.0%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 16 | 21 | 21 | |
| Current EPS | $3.273 | $12.959 | $14.431 | |
| Month Ago EPS | $3.251 | $12.811 | $14.195 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $3.184 | $12.704 | $14.113 | |
| Year/Year Chg | 113.9% | 65.3% | 105.8% | |
| Financials | IQV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $16,983 | $763 | 90% |
|
| Net Income (TTM) (Mil) | $1,375 | ($14) | 89% |
|
| EPS (TTM) | $8.153 | ($0.200) | 93% |
|
| Operating Cash Flow (TTM) (Mil) | $2,819 | $53 | 91% |
|
| Net Cash Flow (TTM) (Mil) | ($130) | ($5) | 13% |
|
| Long-Term Debt (Q1) (Mil) | $13,947 | $270 | 94% |
|
| Enterprise Value (Q1) (Mil) | $55,053 | $2,430 | 93% |
|
| Valuation | IQV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.34 | 3.00 | 83% |
|
| P/E | 29.4 | 43.5 | 67% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.7 | 5.3 | 34% |
|
| Ratios | IQV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 33.0% | 47.6% | 39% |
|
| Net Margin | 8.1% | (2.9%) | 58% |
|
| ROA | 4.7% | (3.2%) | 70% |
|
| ROE | 23.0% | (4.5%) | 83% |
|
| Liabilities to Assets | 78.9% | 43.0% | 74% |
|
| F-Score | 7 | 5 | 84% |
|
IQVIA Holdings Inc. did not pass any screens on 7/30/2026.
